Fixed-Duration Loncastuximab Tesirine May Be Beneficial Earlier on in R/R DLBCL Treatment
September 8th 2023Relapsed/refractory DLBCL is associated with poor prognosis, but preclinical data suggest that adding rituximab to CD19-directed therapy such as loncastuximab tesirine may extend the duration of disease control.
Read More
Choosing CAR T-Cell Therapy vs Bispecific Antibodies in Multiple Myeloma
September 8th 2023Selecting and sequencing treatments in relapsed/refractory multiple myeloma involves balancing various factors due to limited historical data, as explained by Ajai Chari, MD, at the 2023 SOHO Annual Meeting.
Read More
Similar Outcomes With Intensive and Non-Intensive Chemo Pre-Transplant in Older AML
September 7th 2023There was no difference in outcomes observed with intensive vs non-intensive consolidation chemotherapy regimens before allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia.
Read More
Luspatercept Lessens RBC Transfusion Burden in MDS
September 7th 2023Results from the COMMANDS trial led the FDA to approve luspatercept for the treatment of anemia without prior erythropoiesis-stimulating agent use in adult patients with very low- to intermediate-risk MDS who may require regular red blood cell transfusions.
Read More
Is Fixed-Duration Therapy the New Standard of Care in Frontline Chronic Lymphocytic Leukemia?
September 7th 2023Modern fixed-duration therapy has been based on the results shown by 2 approaches: the combination of venetoclax and an anti-CD20 monoclonal antibody and the dual combination of venetoclax and ibrutinib.
Read More
Potential Need to Update Recommendations for CNS Prophylaxis in ALL
September 7th 2023With the emergence of tyrosine kinase inhibitors and targeted immunotherapies in the front line, outcomes for patients with ALL have improved. However, questions about central nervous system involvement and prophylaxis persist.
Read More
Investigation of AYA Ph- ALL Outcomes With Pediatric-Inspired Regimens Needed
September 7th 2023Further investigation into the outcomes of adolescent and young adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia when treated with pediatric-inspired regimens are warranted.
Read More